US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 17:13:20 Source:worldViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Yu Darvish extends scoreless innings streak to 25 in Padres' 9
Next:Socialite Jasmine Hartin enjoys beach snuggle with electrician hunk
You may also like
- NBA playoffs: Edwards leads Wolves to 98
- DJ Stewart hits a 3
- Baywatch star Jeremy Jackson's ex
- Stalking: State Of Fear review
- Not so Cool Britannia! Noel Gallagher gives damning verdict on Keir Starmer
- Delaware judge refuses to fast
- The amazing view... from the best seat on the train! Fascinating driver's
- Extraordinary video captures moment epileptic woman's dogs spot her seizure and run to the rescue
- Kosovo prepares a new draft law on renting prison cells to Denmark after the first proposal failed